These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19587706)

  • 1. Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients.
    Colucci S; Brunetti G; Mori G; Oranger A; Centonze M; Mori C; Cantatore FP; Tamma R; Rizzi R; Liso V; Zallone A; Grano M
    Leukemia; 2009 Nov; 23(11):2139-46. PubMed ID: 19587706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The formation of osteoclasts in multiple myeloma bone disease patients involves the secretion of soluble decoy receptor 3.
    Brunetti G; Oranger A; Mori G; Centonze M; Colaianni G; Rizzi R; Liso V; Zallone A; Grano M; Colucci S
    Ann N Y Acad Sci; 2010 Mar; 1192():298-302. PubMed ID: 20392250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decoy receptor 3 regulates the expression of various genes in rheumatoid arthritis synovial fibroblasts.
    Fukuda K; Miura Y; Maeda T; Takahashi M; Hayashi S; Kurosaka M
    Int J Mol Med; 2013 Oct; 32(4):910-6. PubMed ID: 23912906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis.
    Hayashi S; Miura Y; Nishiyama T; Mitani M; Tateishi K; Sakai Y; Hashiramoto A; Kurosaka M; Shiozawa S; Doita M
    Arthritis Rheum; 2007 Apr; 56(4):1067-75. PubMed ID: 17393415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional characterisation of decoy receptor 3 in Crohn's disease.
    Funke B; Autschbach F; Kim S; Lasitschka F; Strauch U; Rogler G; Gdynia G; Li L; Gretz N; Macher-Goeppinger S; Sido B; Schirmacher P; Meuer SC; Roth W
    Gut; 2009 Apr; 58(4):483-91. PubMed ID: 19039087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
    Shipman CM; Croucher PI
    Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro.
    Tucci M; Ciavarella S; Strippoli S; Brunetti O; Dammacco F; Silvestris F
    Exp Hematol; 2011 Jul; 39(7):773-83.e1. PubMed ID: 21569821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DcR3-TL1A signalling inhibits cytokine-induced proliferation of rheumatoid synovial fibroblasts.
    Takahashi M; Miura Y; Hayashi S; Tateishi K; Fukuda K; Kurosaka M
    Int J Mol Med; 2011 Sep; 28(3):423-7. PubMed ID: 21537832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of the osteoclast in pathogenesis of multiple myeloma].
    Zhang JH; Fu JX; Zhang XH; Sun Y
    Zhonghua Xue Ye Xue Za Zhi; 2007 May; 28(5):323-6. PubMed ID: 17877161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silencing of decoy receptor 3 (DcR3) expression by siRNA in pancreatic carcinoma cells induces Fas ligand-mediated apoptosis in vitro and in vivo.
    Zhou J; Song S; He S; Wang Z; Zhang B; Li D; Zhu D
    Int J Mol Med; 2013 Sep; 32(3):653-60. PubMed ID: 23846297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance.
    Connor JP; Felder M
    Gynecol Oncol; 2008 Nov; 111(2):330-5. PubMed ID: 18723214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysregulation of the receptor activator of NF-kappaB ligand and osteoprotegerin production influence the apoptosis of multiple myeloma patients' bone marrow stromal cells co-cultured with myeloma cells.
    Zdzisińska B; Bojarska-Junak A; Walter-Croneck A; Kandefer-Szerszeń M
    Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):153-63. PubMed ID: 20157786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer.
    Lin WW; Hsieh SL
    Biochem Pharmacol; 2011 Apr; 81(7):838-47. PubMed ID: 21295012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human microvascular endothelial cell activation by IL-1 and TNF-alpha stimulates the adhesion and transendothelial migration of circulating human CD14+ monocytes that develop with RANKL into functional osteoclasts.
    Kindle L; Rothe L; Kriss M; Osdoby P; Collin-Osdoby P
    J Bone Miner Res; 2006 Feb; 21(2):193-206. PubMed ID: 16418775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
    Heider U; Langelotz C; Jakob C; Zavrski I; Fleissner C; Eucker J; Possinger K; Hofbauer LC; Sezer O
    Clin Cancer Res; 2003 Apr; 9(4):1436-40. PubMed ID: 12684416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
    Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
    Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on the pathogenesis of osteolysis in multiple myeloma patients.
    Giuliani N; Colla S; Rizzoli V
    Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An in vitro osteoclast-forming assay to measure myeloma cell-derived osteoclast-activating factors.
    Zannettino AC; Farrugia AN; To LB; Atkins GJ
    Methods Mol Med; 2005; 113():245-56. PubMed ID: 15968108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Decoy Receptor 3 (DcR3, TNFRSF6B) suppresses Th17 immune responses and is abundant in human cerebrospinal fluid.
    Mueller AM; Pedré X; Killian S; David M; Steinbrecher A
    J Neuroimmunol; 2009 Apr; 209(1-2):57-64. PubMed ID: 19269042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
    Sordillo EM; Pearse RN
    Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.